Roy Herbst elected to Friends board of directors

“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.

July 12, 2024

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

July 05, 2024

Vol.50 No.27

By Katerina A. Politi and Roy S. Herbst

In the Archives

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.

July 05, 2024

Vol.50 No.27

In Brief

Miguel Villalona Calero named deputy director of UC Irvine Chao Family CCC

Miguel Villalona Calero was named deputy director of the University of California, Irvine Chao Family Comprehensive Cancer Center and division chief for hematology/oncology. He will start on July 8.

June 28, 2024

Vol.50 No.26

Drugs & Targets

Merck, Qure.ai collaborate to expand lung cancer detection via AI

Merck Global Health Innovation Fund has made a strategic investment into Qure.ai as part of its Series D round.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations

Friends of Cancer Research characterized postmarketing requirements and commitments over the last decade. The perspective article, titled “An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials,” provides insights into FDA’s expectations for representation of race and ethnicity in oncology clinical trials.

June 21, 2024

Vol.50 No.25

Roy Herbst elected to Friends board of directors

YOU MAY BE INTERESTED IN

“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Miguel Villalona Calero named deputy director of UC Irvine Chao Family CCC

Merck, Qure.ai collaborate to expand lung cancer detection via AI

Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations

Renew today!

Subscriber content

Login